NPM1 and acute myeloid leukemia: DNMT3A mutations have no significant effect on clinical outcomes in AML patients with NPM1mut [111], but reduced NPM1 MRD1 after induction is not predictive of overall survival in patients with DNMT3A mutations, and the persistence of DNMT3A mutations is associated with a high-risk of relapse [97, 111, 112].